Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease
Open Access
- 20 November 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 42 (10) , 1747-1753
- https://doi.org/10.1016/j.jacc.2003.05.006
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Prevention of Inflammation-Induced Endothelial DysfunctionCirculation, 2002
- Inflammation and AtherosclerosisCirculation, 2002
- Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial arteryJournal of the American College of Cardiology, 2002
- Cyclooxygenase-2 Blockade Does Not Impair Endothelial Vasodilator Function in Healthy VolunteersCirculation, 2001
- Cardiovascular Thrombotic Events in Controlled, Clinical Trials of RofecoxibCirculation, 2001
- Improved Vascular Endothelial Function After Oral B VitaminsCirculation, 2000
- Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic LesionsThe American Journal of Pathology, 1999
- Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary SyndromesCirculation, 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997